153 related articles for article (PubMed ID: 36310834)
1. Comparative Role of
Hemrom A; Arora G; Damle NA; Bal C
Nucl Med Mol Imaging; 2022 Oct; 56(5):236-244. PubMed ID: 36310834
[TBL] [Abstract][Full Text] [Related]
2. I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma.
Riaz S; Bashir H; Khan SJ; Qazi A
Mol Imaging Radionucl Ther; 2018 Oct; 27(3):121-125. PubMed ID: 30317848
[TBL] [Abstract][Full Text] [Related]
3. Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values.
Černý I; Prášek J; Kašpárková H
Nuklearmedizin; 2016 Aug; 55(4):151-7. PubMed ID: 27054367
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the SIOPEN semi-quantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma.
Radovic B; Artiko V; Sobic-Saranovic D; Trajkovic G; Markovic S; Vujic D; Obradovic V
Neoplasma; 2015; 62(3):449-55. PubMed ID: 25866225
[TBL] [Abstract][Full Text] [Related]
6. [
Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Piccardo A; Puntoni M; Lopci E; Conte M; Foppiani L; Sorrentino S; Morana G; Naseri M; Cistaro A; Villavecchia G; Fanti S; Garaventa A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1046-56. PubMed ID: 24562643
[TBL] [Abstract][Full Text] [Related]
9. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, Treatment Response, and Prognosis: The Role of
Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
[TBL] [Abstract][Full Text] [Related]
11.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
12. Compared to
Kroiss AS; Uprimny C; Shulkin BL; Frech A; Tilg H; Gasser RW; Sprinzl GM; Gruber L; Thomé C; Plangger C; Url C; Fraedrich G; Virgolini IJ
Ann Nucl Med; 2017 Jun; 31(5):357-365. PubMed ID: 28349331
[TBL] [Abstract][Full Text] [Related]
13. [
Wang P; Li T; Liu Z; Jin M; Su Y; Zhang J; Jing H; Zhuang H; Li F
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3097-3106. PubMed ID: 37160439
[TBL] [Abstract][Full Text] [Related]
14. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
[TBL] [Abstract][Full Text] [Related]
15.
Aboian MS; Huang SY; Hernandez-Pampaloni M; Hawkins RA; VanBrocklin HF; Huh Y; Vo KT; Gustafson WC; Matthay KK; Seo Y
J Nucl Med; 2021 Jan; 62(1):43-47. PubMed ID: 32414950
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of iodine-123-labeled metaiodobenzylguanidine single-photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma.
Zhou Z; Wang G; Qian L; Liu J; Yang X; Zhang S; Zhang M; Kan Y; Wang W; Yang J
Quant Imaging Med Surg; 2023 Jun; 13(6):3841-3851. PubMed ID: 37284114
[TBL] [Abstract][Full Text] [Related]
17. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
[TBL] [Abstract][Full Text] [Related]
18. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Piccardo A; Treglia G; Fiz F; Bar-Sever Z; Bottoni G; Biassoni L; Borgwardt L; de Keizer B; Jehanno N; Lopci E; Kurch L; Massollo M; Nadel H; Roca Bielsa I; Shulkin B; Vali R; De Palma D; Cecchin D; Santos AI; Zucchetta P
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):756-767. PubMed ID: 37962616
[TBL] [Abstract][Full Text] [Related]
19. Role of (18)F-DOPA PET/CT and (131)I-MIBG planar scintigraphy in evaluating patients with pheochromocytoma.
Bandopadhyaya GP; Kumar A; Kumari J
Hell J Nucl Med; 2015; 18 Suppl 1():141. PubMed ID: 26665224
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
